CTLT CTLT キャタレント

 CTLTのチャート


 CTLTの企業情報

symbol CTLT
会社名 Catalent Inc (CTLT キャタレント)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 キャタレント(Catalent Inc)は薬品、生物製剤及び顧客・動物健康製品向けの配達技術と開発ソリューションの提供を行う。同社は3つの事業区分により構成される。軟質ゲル技術事業は処方箋・顧客健康ソフト・カプセルまたは軟質ゲルの生産・開発・製造に従事する。薬物配達ソリューション事業は処方箋・顧客・動物健康製品の生産・開発・製造、ブロー・フィル・シール・ユニット・ドーズ製造、生物的細胞株開発、分析と生物分析開発及びテスト・サービスの提供に従事する。臨床供給サービス事業は診療試験薬物と生物製剤の製造・包装・ラベル付け・ストレージ・販売・在庫管理、FastChain臨床供給サービスの提供、臨床電子ソリューションと情報及びグローバルな対照薬供給サービスの提供に従事する。  キャタレントは米国の製薬会社。処方箋薬、市販薬、生物製剤向けに経口剤、注射剤、吸引剤などの発見、開発、受託製造を行う。また、治験薬の製造・供給、各種包装・容器の製造、在庫管理サ―ビスを提供。顧客は米国、欧州、アジア、南米の大手製薬会社や新興製薬企業。  
本社所在地 732 537-6200
代表者氏名 John R. Chiminski
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 732-537-6200
設立年月日 39173
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 10700人
url www.catalent.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 506.80000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 5911.23100
売上高 売上高(百万ドル) 2488.00000
企業価値(EV) 企業価値(EV)(百万ドル) 7903.23100
当期純利益 当期純利益(百万ドル) 132.90000
決算概要 決算概要 BRIEF: For the six months ended 31 December 2018 Catalent Inc revenues increased 2% to $1.17B. Net income before extraordinary items increased 24% to $34.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Debt refinancing costs decrease of 64% to $4.2M (expense) Foreign currency (gains) and losses decrease of 65% to $2.4M (expense).

 CTLTのテクニカル分析


 CTLTのニュース

   Catalent To Boost Output Of Finished Vials For Moderna's COVID-19 Shot: WSJ  2021/04/06 10:46:49 Benzinga
Catalent Inc (NYSE: CTLT ) is reportedly expanding its U.S. production of Moderna Inc’s (NASDAQ: MRNA ) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent helps Moderna fill its vaccine in vials for shipment. This new deal builds on Catalent’s agreement from last June to help produce Moderna’s vaccine. Catalent is dedicating a high-speed production line at its Indiana plant to do fill-finish as part … Full story available on Benzinga.com
   J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Secures Key FDA Clearance  2021/03/24 06:13:34 Benzinga
Johnson & Johnson’s (NYSE: JNJ ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT ) secured a key U.S. regulator clearance, Bloomberg News reported on Tuesday. What Happened: A U.S. Food and Drug Administration’s emergency-use clearance received Tuesday will allow Catalent's facility in Bloomington, Indiana, to manufacture and ship millions of doses helping boost the vaccination supply. White House Press Secretary Jen Psaki on Tuesday said the U.S. is allocating 27 million doses across all channels this week, of … Full story available on Benzinga.com
   Covid-19 Impact on Pharmaceutical Intermediates Market 2021-2025: Business Growth by Top Key Company’s - BASF, Lonza, Catalent, Patheon, Jubilant, Granules, Ganesh, Chemcon, Porton  2021/03/22 15:33:36 OpenPR
Global Pharmaceutical Intermediates Market Synopsis: The report covers a forecast and an analysis of the Pharmaceutical Intermediates Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020
   Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)  2021/03/22 11:15:00 Business Wire
TORONTO--(BUSINESS WIRE)--Cybin signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
   ΗΠΑ:Επέκταση παραγωγής εμβολίου της J&J στην Ιταλία  2021/03/17 07:21:00 Sigmalive Cyprus
Η πολυεθνική εταιρία Catalent Inc προγραμματίζει την επέκταση της παραγωγής του εμβολίου της Johnson & Johnson (J&J) κατά της COVID-19 που παράγει στην Ευρώπη, ώστε να μπορέσει να παραγάγει περισσότερες δόσεις, όπως ανέφερε χθες η εφημερίδα «The Wall Street Journal». Η εφημερίδα επικαλέστηκε πηγές που έχουν λάβει γνώση για το ζήτημα αυτό. Η αναφερόμενη φαρμακευτική εταιρία θα ενεργοποιήσει μία δεύτερη γραμμή παραγωγής του εμβολίου της J&J στο εργοστάσιο της στην πόλη Ανάγκνι της Ιταλίας, στη διάρκεια του τέταρτου τριμήνου, σύμφωνα με το δημοσίευμα. Πηγή: ΑΠΕ-ΜΠΕ
   Catalent To Boost Output Of Finished Vials For Moderna's COVID-19 Shot: WSJ  2021/04/06 10:46:49 Benzinga
Catalent Inc (NYSE: CTLT ) is reportedly expanding its U.S. production of Moderna Inc’s (NASDAQ: MRNA ) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent helps Moderna fill its vaccine in vials for shipment. This new deal builds on Catalent’s agreement from last June to help produce Moderna’s vaccine. Catalent is dedicating a high-speed production line at its Indiana plant to do fill-finish as part … Full story available on Benzinga.com
   J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Secures Key FDA Clearance  2021/03/24 06:13:34 Benzinga
Johnson & Johnson’s (NYSE: JNJ ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT ) secured a key U.S. regulator clearance, Bloomberg News reported on Tuesday. What Happened: A U.S. Food and Drug Administration’s emergency-use clearance received Tuesday will allow Catalent's facility in Bloomington, Indiana, to manufacture and ship millions of doses helping boost the vaccination supply. White House Press Secretary Jen Psaki on Tuesday said the U.S. is allocating 27 million doses across all channels this week, of … Full story available on Benzinga.com
   Covid-19 Impact on Pharmaceutical Intermediates Market 2021-2025: Business Growth by Top Key Company’s - BASF, Lonza, Catalent, Patheon, Jubilant, Granules, Ganesh, Chemcon, Porton  2021/03/22 15:33:36 OpenPR
Global Pharmaceutical Intermediates Market Synopsis: The report covers a forecast and an analysis of the Pharmaceutical Intermediates Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020
   Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)  2021/03/22 11:15:00 Business Wire
TORONTO--(BUSINESS WIRE)--Cybin signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
   ΗΠΑ:Επέκταση παραγωγής εμβολίου της J&J στην Ιταλία  2021/03/17 07:21:00 Sigmalive Cyprus
Η πολυεθνική εταιρία Catalent Inc προγραμματίζει την επέκταση της παραγωγής του εμβολίου της Johnson & Johnson (J&J) κατά της COVID-19 που παράγει στην Ευρώπη, ώστε να μπορέσει να παραγάγει περισσότερες δόσεις, όπως ανέφερε χθες η εφημερίδα «The Wall Street Journal». Η εφημερίδα επικαλέστηκε πηγές που έχουν λάβει γνώση για το ζήτημα αυτό. Η αναφερόμενη φαρμακευτική εταιρία θα ενεργοποιήσει μία δεύτερη γραμμή παραγωγής του εμβολίου της J&J στο εργοστάσιο της στην πόλη Ανάγκνι της Ιταλίας, στη διάρκεια του τέταρτου τριμήνου, σύμφωνα με το δημοσίευμα. Πηγή: ΑΠΕ-ΜΠΕ
   J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Secures Key FDA Clearance  2021/03/24 06:13:34 Benzinga
Johnson & Johnson’s (NYSE: JNJ ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT ) secured a key U.S. regulator clearance, Bloomberg News reported on Tuesday. What Happened: A U.S. Food and Drug Administration’s emergency-use clearance received Tuesday will allow Catalent's facility in Bloomington, Indiana, to manufacture and ship millions of doses helping boost the vaccination supply. White House Press Secretary Jen Psaki on Tuesday said the U.S. is allocating 27 million doses across all channels this week, of … Full story available on Benzinga.com
   Covid-19 Impact on Pharmaceutical Intermediates Market 2021-2025: Business Growth by Top Key Company’s - BASF, Lonza, Catalent, Patheon, Jubilant, Granules, Ganesh, Chemcon, Porton  2021/03/22 15:33:36 OpenPR
Global Pharmaceutical Intermediates Market Synopsis: The report covers a forecast and an analysis of the Pharmaceutical Intermediates Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020
   Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)  2021/03/22 11:15:00 Business Wire
TORONTO--(BUSINESS WIRE)--Cybin signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
   ΗΠΑ:Επέκταση παραγωγής εμβολίου της J&J στην Ιταλία  2021/03/17 07:21:00 Sigmalive Cyprus
Η πολυεθνική εταιρία Catalent Inc προγραμματίζει την επέκταση της παραγωγής του εμβολίου της Johnson & Johnson (J&J) κατά της COVID-19 που παράγει στην Ευρώπη, ώστε να μπορέσει να παραγάγει περισσότερες δόσεις, όπως ανέφερε χθες η εφημερίδα «The Wall Street Journal». Η εφημερίδα επικαλέστηκε πηγές που έχουν λάβει γνώση για το ζήτημα αυτό. Η αναφερόμενη φαρμακευτική εταιρία θα ενεργοποιήσει μία δεύτερη γραμμή παραγωγής του εμβολίου της J&J στο εργοστάσιο της στην πόλη Ανάγκνι της Ιταλίας, στη διάρκεια του τέταρτου τριμήνου, σύμφωνα με το δημοσίευμα. Πηγή: ΑΠΕ-ΜΠΕ
   Japan’s Takeda, Germany’s IDT Biologika to make Johnson & Johnson's single-dose Covid-19 vaccine  2021/03/15 18:19:40 The Sun Daily
BENGALURU/BERLIN: Japan's Takeda Pharmaceutical Co Ltd said on Monday it has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's single-dose Covid-19 vaccine. J&J's vaccine, authorized in the United States on Feb 27, is the first single-dose coronavirus vaccine alongside two-shot vaccines from Pfizer/BioNTech and Moderna Inc. The latest move will help ease some concerns in Europe about J&J's ability to meet production goals. The drugmaker has been working to expand the manufacturing capacity for its vaccine and previously tapped contract manufacturers such as Catalent and Emergent to scale up production and meet global supply goals. Merck & Co and France's Sanofi agreed to help make J&J's vaccine earlier this year. A European Union official told Reuters earlier this month J&J had flagged possible supply issues that may affect its plans to deliver 55 million vaccine doses to the bloc in the second quarter of the year. Under the contract, the capacity at IDT's Dessau site, previously reserved to make Takeda's dengue vaccine candidate, will be used to make J&J's Covid-19 vaccine for worldwide distribution.

 関連キーワード  (医薬品 米国株 CTLT キャタレント CTLT )

 twitter  (公式ツイッターやCEOツイッターなど)